Cell Genesys Restructures After Second Clinical Trial Failure with Prostate Cancer...

With development halted, company will cut 75% of its staff this year, and more reductions are expected next year. Cell Genesys reported the halt of...

Cell Genesys’ Value Drops 74% with Suspension of a Phase III...

Review showed 20 more deaths in treatment arm versus control arm of study. Cell Genesys is halting a late-stage investigation of its prostate cancer immunotherapy...

ANTIBIOTICS ENHANCE RNAI CAPABILITIES

- Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine

Althea and Protein’eXpert to Couple Respective Manufacturing and Research Services

Althea’s cGMP expertise will be combined with Protein’eXpert’s drug and vaccine development offerings. Althea Technologies and Protein'eXpert plan on offering their services under a complementary...

FDA Hits Merck & Co. with Double Whammy for Gardasil Label...

Agency denied approval in nonvaccine HPV types and identified questions regarding the use of the vaccine in older women. FDA issued negative reviews of two...

Takeda Snags Cell Genesys’ Prostate Cancer Immunotherapy in $320M Agreement

All development and commercialization rights for this Phase III treatment will transfer to Takeda for $50 million upfront. Takeda Pharmaceutical has bought the rights to Cell...

Defending Pharma Companies

Marc-André Gagnon’s point of view piece in the February 15 issue of GEN maintains that, by and large, pharmaceutical companies have departed from the...

Althea Technologies Spins Out Diagnostics Business

New firm will focus on genetic testing services and diagnostic products related to oncology applications. Althea Technologies spun out an independent company to commercialize its genetic...

PPD Plans to Acquire InnoPharm to Augment Its Eastern European Presence

CRO obtains offices in Russia and Ukraine. PPD has agreed to purchase InnoPharm to expand its CRO services into Russia and Ukraine. “With more than...

Quintessence Retains Althea Technologies to Produce First Lead Candidate

IND filing for protein oncology drug planned in first quarter. Althea Technologies was awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to...